Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 4/20 | 0.56 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 8/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31672345 | 0.92 | KRAS (0.67) | KRASSHMT2GAAEGFRERBB2 | |
| SCHEMBL16117831 | 0.92 | KRAS (0.67) | KRASSHMT2GAAEGFRERBB2 | |
| SCHEMBL16122360 | 0.87 | KRAS (0.57) | KRASGAAEGFRERBB2 | |
| SCHEMBL16122737 | 0.87 | KRAS (0.66) | KRASSHMT2GAAEGFRERBB2 | |
| SCHEMBL21302149 | 0.84 | KRAS (0.80) | KRASSHMT2GAAEGFRERBB2 | |
| SCHEMBL16122678 | 0.84 | KRAS (0.57) | KRASSHMT2GAAEGFRERBB2 | |
| SCHEMBL16122355 | 0.84 | KRAS (0.58) | KRASSHMT2GAAEGFRERBB2 | |
| SCHEMBL16122814 | 0.83 | KRAS (0.50) | KRASGAAEGFRERBB2 | |
| SCHEMBL16122631 | 0.82 | KRAS (0.76) | KRASSHMT2GAAEGFRERBB2 | |
| SCHEMBL16117832 | 0.82 | KRAS (0.83) | KRASSHMT2ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | KRAS 1/4885SHMT2 1327/4885GAA 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.